July 11, 2018

A new generation of engineered vaccine candidates enters clinical testing.


For the first time, researchers are advancing a new class of vaccine candidates specifically engineered to kickstart the induction of broadly neutralizing antibodies that can face up to the extreme genetic variation of the virus and all its circulating forms. In this issue, we detail this exciting progress as well as the advances in developing the broadly neutralizing antibodies themselves for HIV prevention, an effort referred to as passive administration.

Read the full issue

IR Vol22No2 2018 Cover with border